Abbott has acquired a commercial-stage medical device company, Walk Vascular, for an undisclosed amount to expand its peripheral vascular offerings.

With the acquisition, Abbott gained rights to Walk Vascular’s less-invasive mechanical aspiration thrombectomy system for peripheral blood clot removal.

The JETi Peripheral Thrombectomy System and JETi AIO (All In One) Peripheral Thrombectomy System of Walk Vascular are aspiration systems used to remove intravascular clots known as thrombus.

Such clots can reduce blood flow, thereby causing severe complications in patients.

These systems can disintegrate and remove clots from the peripheral vascular system, as well as decrease the risk of dislodged clots.

Furthermore, the JETi Peripheral Thrombectomy Systems have obtained 510(k) clearance from the US Food and Drug Administration for aspiration and disintegration of soft emboli as well as thrombus from the peripheral vasculature.

They are also approved in various other countries and hold the CE mark in Europe.

In addition, the systems are supported by real-world clinical data and Walk Vascular is presently enrolling up to 250 patients in the US and Europe in the JETi Registry study.

A prospective, multi-centre trial, JETi Registry is assessing the safety and efficacy of the JETi Peripheral Thrombectomy System in people with acute peripheral thrombus.

Abbott noted that the peripheral thrombectomy systems of Walk Vascular will be integrated into its current portfolio of endovascular products.

Abbott vascular business senior vice-president Julie Tyler said: “The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care.

“Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”

Last month, the company reported data from the GUIDE-HF clinical trial, where its CardioMEMS HF System reduced mortality in New York Heart Association (NYHA) Class II, III and IV heart failure patients.